Angiotensin II, From Vasoconstrictor to Growth Factor
- 28 February 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 114 (5) , 754-757
Abstract
Angiotensin II (Ang II) is today considered as one of the essential factors in the pathophysiology of cardiovascular disease, producing acute, hemodynamic and chronic, pleiotropic effects. Although now it is widely accepted that these chronic effects are important, Ang II was initially considered only a short-acting, vasoactive hormone. This view was modified a quarter of a century ago when Dr. Owens and his group published a paper in Circulation Research with initial evidence that Ang II can act as a growth factor that regulates cell hypertrophy. They showed in series of elegant experiments that Ang II promotes hypertrophy and hyperploidy of cultured rat aortic smooth muscle cells. However, Ang II had no effect on hyperplasia. These findings led to a paradigm shift in our understanding of the roles of growth factors and vasoactive substances in cardiovascular pathology and helped to redirect basic and clinical renin-angiotensin system research over the next twenty-five years. Ang II is now known to be a pleiotropic hormone that utilizes multiple signaling pathways to influence most processes that contribute to the development and progression of cardiovascular diseases, ranging from hypertrophy, endothelial dysfunction, cardiac remodeling, fibrosis, and inflammation to oxidative stress.Keywords
This publication has 36 references indexed in Scilit:
- 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC)Journal Of Hypertension, 2013
- Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patientsEuropean Heart Journal, 2012
- Myocardin is differentially required for the development of smooth muscle cells and cardiomyocytesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Myocardin and Prx1 Contribute to Angiotensin II-Induced Expression of Smooth Muscle α-ActinCirculation Research, 2004
- Inhibition of EGF-Induced Vasoconstriction in Isolated Rabbit Aortic Rings with the Tyrosine Kinase Inhibitor RG50864Biochemical and Biophysical Research Communications, 1993
- Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)The American Journal of Cardiology, 1988
- Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats.Hypertension, 1987
- Low-dose captopril therapy in mild and moderate hypertension. Randomized comparison of twice daily vs three times daily doses.Hypertension, 1983
- Hemodynamic effects of captopril in patients with severe chronic heart failureThe American Journal of Cardiology, 1982
- Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor.Circulation, 1980